Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/103066
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | González Ortega, Itxaso | - |
dc.contributor.author | Alberich, Susana | - |
dc.contributor.author | Echeburúa, Enrique | - |
dc.contributor.author | Aizpuru, Felipe | - |
dc.contributor.author | Millán, Eduardo | - |
dc.contributor.author | Vieta i Pascual, Eduard, 1963- | - |
dc.contributor.author | Matute, Carlos | - |
dc.contributor.author | González-Pinto, Ana | - |
dc.date.accessioned | 2016-10-31T14:21:42Z | - |
dc.date.available | 2016-10-31T14:21:42Z | - |
dc.date.issued | 2015-04-15 | - |
dc.identifier.issn | 1932-6203 | - |
dc.identifier.uri | http://hdl.handle.net/2445/103066 | - |
dc.description.abstract | BACKGROUND: Although depressive symptoms in first episode psychosis have been associated with cannabis abuse, their influence on the long-term functional course of FEP patients who abuse cannabis is unknown. The aims of the study were to examine the influence of subclinical depressive symptoms on the long-term outcome in first episode-psychosis patients who were cannabis users and to assess the influence of these subclinical depressive symptoms on the ability to quit cannabis use. METHODS: 64 FEP patients who were cannabis users at baseline were followed-up for 5 years. Two groups were defined: (a) patients with subclinical depressive symptoms at least once during follow-up (DPG), and (b) patients without subclinical depressive symptoms during follow-up (NDPG). Psychotic symptoms were measured using the Positive and Negative Syndrome Scale (PANSS), depressive symptoms using the Hamilton Depression Rating Scale (HDRS)-17, and psychosocial functioning was assessed using the Global Assessment of Functioning (GAF). A linear mixed-effects model was used to analyze the combined influence of cannabis use and subclinical depressive symptomatology on the clinical outcome. RESULTS: Subclinical depressive symptoms were associated with continued abuse of cannabis during follow-up (β= 4.45; 95% confidence interval [CI]: 1.78 to 11.17; P = .001) and with worse functioning (β = -5.50; 95% CI: -9.02 to -0.33; P = .009). CONCLUSIONS: Subclinical depressive symptoms and continued cannabis abuse during follow-up could be predictors of negative outcomes in FEP patients. | - |
dc.format.extent | 12 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Public Library of Science (PLoS) | - |
dc.relation.isformatof | Reproducció del document publicat a: http://dx.doi.org/10.1371/journal.pone.0123707 | - |
dc.relation.ispartof | PLoS One, 2015, vol. 10, num. 4, p. e0123707 | - |
dc.relation.uri | http://dx.doi.org/10.1371/journal.pone.0123707 | - |
dc.rights | cc-by (c) González Ortega, Itxaso et al., 2015 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es | - |
dc.source | Articles publicats en revistes (Medicina) | - |
dc.subject.classification | Depressió psíquica | - |
dc.subject.classification | Cànnabis | - |
dc.subject.classification | Psicosi | - |
dc.subject.classification | Psicopatologia | - |
dc.subject.other | Mental depression | - |
dc.subject.other | Cannabis | - |
dc.subject.other | Psychoses | - |
dc.subject.other | Pathological psychology | - |
dc.title | Subclinical depressive symptoms and continued cannabis use: predictors of negative outcomes in first episode psychosis | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 651824 | - |
dc.date.updated | 2016-10-31T14:21:48Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 25875862 | - |
Appears in Collections: | Articles publicats en revistes (Medicina) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
651824.pdf | 185.22 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License